Introducing COBENFY
The first new class* of schizophrenia treatment in over 3 decades1-4
Three reasons to believe in COBENFY—the first and only M1/M4 muscarinic agonist1,3,5*
FIRST IN CLASS* & HIGHLY SELECTIVE1,3,5†
DEPTH & BREADTH OF EFFICACY‡§
SAFETY & TOLERABILITY PROFILE
The mechanism of action of COBENFY in the treatment of schizophrenia is unclear1
* | COBENFY is a combination of xanomeline (M1/M4 muscarinic agonist) and trospium chloride (muscarinic antagonist).1 |
† | Xanomeline binds to muscarinic receptors M1 to M5 with comparable affinity and exhibits higher agonist activity at the M1 and M4 receptors.1 |
‡ | Two randomized, double-blind, placebo-controlled, phase 3 studies assessed the safety and efficacy (change in PANSS total score from baseline at Week 5) of COBENFY—EMERGENT-2 (N=252) and EMERGENT-3 (N=256).3,6-8 See additional study design details. |
§ | EMERGENT-2 and EMERGENT-3 trial results evaluating change in PANSS total score from baseline at 5 weeks vs placebo (EMERGENT-2: -21.2 vs -11.6, P<0.0001; EMERGENT-3: -20.6 vs -12.2, P<0.001). Change from baseline at Week 5 in PANSS positive subscale score was also assessed as a secondary end point and achieved statistical significance vs placebo (EMERGENT-2: -6.8 vs -3.9, P<0.0001, EMERGENT-3: -7.1 vs -3.6, P<0.001).3,6 |
PANSS=Positive and Negative Syndrome Scale. |
Capsules not shown at actual size.
Get your patients started on COBENFY today
References:
- COBENFY. Prescribing Information. Bristol Myers Squibb Company; 2024.
- Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022;179(9):611-627.
- Kaul I, Sawchak S, Walling DP, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2024;81(8):749-756.
- Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14(3):750-761.
- Dean B, Bakker G, Ueda HR, Tobin AB, Brown A, Kanaan RAA. A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Front Cell Neurosci. 2023;17:1124333.
- Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403(10422):160-170.
- Data on file. Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Boston, MA.
- Kaul I, Citrome L, Sawchak S, et al. Efficacy of KarXT (xanomeline–trospium) in schizophrenia: pooled results from the randomized, double-blind, placebo-controlled EMERGENT trials. Poster presented at: Neuroscience Education Institute Congress; November 9-12, 2023; Colorado Springs, CO.